(GNFT) Genfit S.A. - Overview
Sector: HealthcareIndustry: Biotechnology | Exchange PA (France) | Currency EUR | Market Cap: 488m | Total Return 159.5% in 12m
Stock: Drug Candidates, Diagnostics, Liver Disease, Metabolic Disease
Total Rating 40
Risk 32
Buy Signal -0.07
| Risk 5d forecast | |
|---|---|
| Volatility | 49.7% |
| Relative Tail Risk | -9.48% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.16 |
| Alpha | 147.38 |
| Character TTM | |
|---|---|
| Beta | 0.608 |
| Beta Downside | 0.131 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.09% |
| CAGR/Max DD | 0.74 |
Description: GNFT Genfit S.A. March 05, 2026
Genfit S.A. is a late-stage biopharmaceutical company focused on metabolic and liver diseases. The company develops drug candidates and diagnostic solutions. Biopharmaceutical companies typically incur significant R&D costs.
Its primary drug candidate, Elafibranor, is in Phase III for primary biliary cholangitis. Genfit also develops NIS4 technology for diagnosing nonalcoholic steatohepatitis (NASH) and fibrosis. NASH drug development is a competitive and challenging area for pharmaceutical companies.
Other pipeline assets include VS-01 for Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD), GNS561 for cholangiocarcinoma (CCA), and VS-01-ACLF/Nitazoxanide (NTZ) for acute-on-chronic liver failure. The company also has preclinical programs.
Genfit has licensing agreements, including one with Labcorp for the NASHnext diagnostic test and another with Genoscience Pharma for GNS561. Licensing agreements are a common strategy for biopharmaceutical companies to share development costs and expand market reach. Further research on ValueRay can provide more in-depth analysis of their intellectual property and partnerships.
Headlines to watch out for
- Elafibranor Phase III trial results drive stock volatility
- NIS4 diagnostic commercialization impacts revenue growth
- VS-01 development pipeline progress affects valuation
- Licensing agreements with Labcorp and Genoscience generate income
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -16.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 9.28 > 1.0 |
| NWC/Revenue: 94.49% < 20% (prev 365.9%; Δ -271.5% < -1%) |
| CFO/TA -0.21 > 3% & CFO -45.3m > Net Income -16.5m |
| Net Debt (31.4m) to EBITDA (1.39m): 22.54 < 3 |
| Current Ratio: 3.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.8m) vs 12m ago 0.17% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 61.70% > 50% (prev 11.73%; Δ 49.97% > 0%) |
| Interest Coverage Ratio: -0.26 > 6 (EBITDA TTM 1.39m / Interest Expense TTM 7.12m) |
Altman Z'' -5.10
| A: 0.53 (Total Current Assets 155.4m - Total Current Liabilities 41.6m) / Total Assets 216.7m |
| B: -1.84 (Retained Earnings -399.4m / Total Assets 216.7m) |
| C: -0.01 (EBIT TTM -1.85m / Avg Total Assets 195.3m) |
| D: -2.35 (Book Value of Equity -386.7m / Total Liabilities 164.2m) |
| Altman-Z'' Score: -5.10 = D |
Beneish M -0.16
| DSRI: 0.19 (Receivables 36.9m/32.7m, Revenue 120.5m/20.4m) |
| GMI: 0.99 (GM 99.75% / 98.33%) |
| AQI: 0.81 (AQ_t 0.25 / AQ_t-1 0.30) |
| SGI: 5.91 (Revenue 120.5m / 20.4m) |
| TATA: 0.13 (NI -16.5m - CFO -45.3m) / TA 216.7m) |
| Beneish M-Score: -0.16 (Cap -4..+1) = D |
What is the price of GNFT shares?
As of March 28, 2026, the stock is trading at EUR 8.50 with a total of 191,151 shares traded.
Over the past week, the price has changed by -6.64%, over one month by -3.90%, over three months by +60.68% and over the past year by +159.54%.
Over the past week, the price has changed by -6.64%, over one month by -3.90%, over three months by +60.68% and over the past year by +159.54%.
Is GNFT a buy, sell or hold?
Genfit S.A. has no consensus analysts rating.
What are the forecasts/targets for the GNFT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.6 | 60% |
| Analysts Target Price | - | - |
GNFT Fundamental Data Overview March 25, 2026
Market Cap USD = 487.7m (421.8m EUR * 1.1562 EUR.USD)
P/E Forward = 7.5472
P/S = 9.3476
P/B = 8.3248
Revenue TTM = 120.5m EUR
EBIT TTM = -1.85m EUR
EBITDA TTM = 1.39m EUR
Long Term Debt = 1.22m EUR (from longTermDebt, last quarter)
Short Term Debt = 17.6m EUR (from shortTermDebt, last quarter)
Debt = 138.9m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 31.4m EUR (from netDebt column, last quarter)
Enterprise Value = 549.6m EUR (421.8m + Debt 138.9m - CCE 11.1m)
Interest Coverage Ratio = -0.26 (Ebit TTM -1.85m / Interest Expense TTM 7.12m)
EV/FCF = -11.65x (Enterprise Value 549.6m / FCF TTM -47.2m)
FCF Yield = -8.58% (FCF TTM -47.2m / Enterprise Value 549.6m)
FCF Margin = -39.14% (FCF TTM -47.2m / Revenue TTM 120.5m)
Net Margin = -13.68% (Net Income TTM -16.5m / Revenue TTM 120.5m)
Gross Margin = unknown ((Revenue TTM 120.5m - Cost of Revenue TTM 300k) / Revenue TTM)
Tobins Q-Ratio = 2.54 (Enterprise Value 549.6m / Total Assets 216.7m)
Interest Expense / Debt = 1.72% (Interest Expense 2.40m / Debt 138.9m)
Taxrate = 18.41% (340k / 1.85m)
NOPAT = -1.51m (EBIT -1.85m * (1 - 18.41%)) [loss with tax shield]
Current Ratio = 3.74 (Total Current Assets 155.4m / Total Current Liabilities 41.6m)
Debt / Equity = 2.65 (Debt 138.9m / totalStockholderEquity, last quarter 52.5m)
Debt / EBITDA = 22.54 (Net Debt 31.4m / EBITDA 1.39m)
Debt / FCF = -0.67 (negative FCF - burning cash) (Net Debt 31.4m / FCF TTM -47.2m)
Total Stockholder Equity = 71.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.44% (Net Income -16.5m / Total Assets 216.7m)
RoE = -22.98% (Net Income TTM -16.5m / Total Stockholder Equity 71.8m)
RoCE = -2.54% (EBIT -1.85m / Capital Employed (Equity 71.8m + L.T.Debt 1.22m))
RoIC = -1.28% (negative operating profit) (NOPAT -1.51m / Invested Capital 118.3m)
WACC = 6.46% (E(421.8m)/V(560.7m) * Re(8.12%) + D(138.9m)/V(560.7m) * Rd(1.72%) * (1-Tc(0.18)))
Discount Rate = 8.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.08%
[DCF] Fair Price = unknown (Cash Flow -47.2m)
EPS Correlation: 1.85 | EPS CAGR: 210.3% | SUE: 0.0 | # QB: 0
Revenue Correlation: 57.41 | Revenue CAGR: 2.43k% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=0.21 | Chg7d=+0.830 | Chg30d=+0.936 | Revisions Net=+3 | Growth EPS=+175.3% | Growth Revenue=+13.2%
P/E Forward = 7.5472
P/S = 9.3476
P/B = 8.3248
Revenue TTM = 120.5m EUR
EBIT TTM = -1.85m EUR
EBITDA TTM = 1.39m EUR
Long Term Debt = 1.22m EUR (from longTermDebt, last quarter)
Short Term Debt = 17.6m EUR (from shortTermDebt, last quarter)
Debt = 138.9m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 31.4m EUR (from netDebt column, last quarter)
Enterprise Value = 549.6m EUR (421.8m + Debt 138.9m - CCE 11.1m)
Interest Coverage Ratio = -0.26 (Ebit TTM -1.85m / Interest Expense TTM 7.12m)
EV/FCF = -11.65x (Enterprise Value 549.6m / FCF TTM -47.2m)
FCF Yield = -8.58% (FCF TTM -47.2m / Enterprise Value 549.6m)
FCF Margin = -39.14% (FCF TTM -47.2m / Revenue TTM 120.5m)
Net Margin = -13.68% (Net Income TTM -16.5m / Revenue TTM 120.5m)
Gross Margin = unknown ((Revenue TTM 120.5m - Cost of Revenue TTM 300k) / Revenue TTM)
Tobins Q-Ratio = 2.54 (Enterprise Value 549.6m / Total Assets 216.7m)
Interest Expense / Debt = 1.72% (Interest Expense 2.40m / Debt 138.9m)
Taxrate = 18.41% (340k / 1.85m)
NOPAT = -1.51m (EBIT -1.85m * (1 - 18.41%)) [loss with tax shield]
Current Ratio = 3.74 (Total Current Assets 155.4m / Total Current Liabilities 41.6m)
Debt / Equity = 2.65 (Debt 138.9m / totalStockholderEquity, last quarter 52.5m)
Debt / EBITDA = 22.54 (Net Debt 31.4m / EBITDA 1.39m)
Debt / FCF = -0.67 (negative FCF - burning cash) (Net Debt 31.4m / FCF TTM -47.2m)
Total Stockholder Equity = 71.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.44% (Net Income -16.5m / Total Assets 216.7m)
RoE = -22.98% (Net Income TTM -16.5m / Total Stockholder Equity 71.8m)
RoCE = -2.54% (EBIT -1.85m / Capital Employed (Equity 71.8m + L.T.Debt 1.22m))
RoIC = -1.28% (negative operating profit) (NOPAT -1.51m / Invested Capital 118.3m)
WACC = 6.46% (E(421.8m)/V(560.7m) * Re(8.12%) + D(138.9m)/V(560.7m) * Rd(1.72%) * (1-Tc(0.18)))
Discount Rate = 8.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.08%
[DCF] Fair Price = unknown (Cash Flow -47.2m)
EPS Correlation: 1.85 | EPS CAGR: 210.3% | SUE: 0.0 | # QB: 0
Revenue Correlation: 57.41 | Revenue CAGR: 2.43k% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=0.21 | Chg7d=+0.830 | Chg30d=+0.936 | Revisions Net=+3 | Growth EPS=+175.3% | Growth Revenue=+13.2%